Hyderabad-based Suven LifeSciences is a pharma firm written about by Trendlyne first in Feb 2017, when the firm won multiple patents for the treatment of Alzheimer's and other neurodegenerative diseases. The company has now received product patent recognition from Norway and Eurasia for products in the same neuro-degenerative space. The firm's share price has been rising on the news, despite the tepid market. The company has been cash positive despite significant spending on R&D - annually, Suven spends around 14% of its sales on proprietary NCE research, which has been till date, not a revenue generator.

A note of caution however remains in that Alzheimer's is a notoriously difficult disease to treat, and therapy tends to fail in large-scale usage after successful trials. One of the drugs in development by Suven, RVT-101, has released phase-2 data that was disappointing.

Suven is one of the smaller firms in the pharma space with a distinct R&D focus that has paid off so far in rising YoY revenues an EBITDA margins, which as per the most recent quarter are over 46%.